The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Abstract
Background: Inflammation and oxidative stress are associated with atherosclerosis. Myeloperoxidase (MPO) is linked to both inflammation and oxidative stress by its location in leukocytes and its role in catalyzing the formation of oxidizing agents. Recent evidence suggests that MPO activity precipitates atherogenesis. Measurement of MPO in plasma may therefore contribute to cardiovascular disease (CVD) risk stratification. Content: Cross-sectional studies, case-control studies, and prospective-cohort studies investigating the relation between MPO and CVD have been evaluated. Differences in study populations, sample materials, sample handling, and assays were ascertained. Potential causal mechanisms linking MPO to accelerated atherosclerosis are discussed here. A majority of studies indicate that measurement of MPO in plasma was associated with improved CVD risk stratification above and beyond risk stratification results obtained with markers used in routine clinical practice. However, comparison of these epidemiological studies with regard to MPO and outcome is hampered because the reported MPO concentration depends on the assay method, sampling material, and preanalytical and analytical procedures. The link between MPO and CVD can, at least partly, be explained by MPO-dependent oxidation of LDL and HDL, subsequently leading to cholesterol accumulation in the arterial wall. Furthermore, MPO may reduce the bioavailability of nitric oxide, resulting in endothelial dysfunction. Finally, MPO destabilizes atherosclerotic plaques. Summary: Increasing evidence suggests that MPO is causally linked to atherosclerosis and its measurement may improve CVD risk estimation. Before MPO can be used in routine clinical practice, however, standardization of sampling and laboratory procedures is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hazen, S. L., & Heinecke, J. W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119379 · Cited by 842
Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T. O., Singh, P., Anantharamaiah, G. M., Chait, A., Brunzell, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405292101 · Cited by 454
Malle, E., Waeg, G., Schreiber, R., Gröne, E. F., Sattler, W., & Gröne, H. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01498.x · Cited by 245
Plasma myeloperoxidase is related to the severity of coronary artery disease
Düzgünçinar, Ö., Yavuz, B., Hazirolan, T., Deniz, A., Tokgözoglu, S. L., Akata, D., & Demirpençe, E. (2008) · Acta Cardiologica · doi:10.2143/ac.63.2.2029520 · Cited by 54
Cited by
Biological markers of oxidative stress: Applications to cardiovascular research and practice
Ho, E., Karimi Galougahi, K., Liu, C.-C., Bhindi, R., & Figtree, G. A. (2013) · Redox Biology · doi:10.1016/j.redox.2013.07.006 · Cited by 811
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
Yoshida, H., & Kisugi, R. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.08.038 · Cited by 288
Air pollution and circulating biomarkers of oxidative stress
Delfino, R. J., Staimer, N., & Vaziri, N. D. (2011) · Air Quality, Atmosphere & Health · doi:10.1007/s11869-010-0095-2 · Cited by 181
Davies, M. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107685 · Cited by 119
Metadata
- Authors
- Schindhelm, R. K., van der Zwan, L. P., Teerlink, T., & Scheffer, P. G.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-01
- Volume
- 55
- Issue
- 8
- Pages
- 1462-1470
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2105868148
- Cited by
- 234
- References
- 4
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification? https://app.cochat.ai/papers/10.1373/clinchem.2009.126029
- The paper
- Schindhelm, R. K., van der Zwan, L. P., Teerlink, T., & Scheffer, P. G. (2009). Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification? Clinical Chemistry. https://doi.org/10.1373/clinchem.2009.126029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.